ブルートンのチロシンキナーゼ阻害剤:がん,自己免疫疾患,GVHD,COVID-19に対する多用途の治療法

Swati Paliwal^1,2, Uma Agarwal^1,3, Rajiv Kumar Tonk¹

¹Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar Sector 3, M-B Road, New Delhi, 110017, India.

Mini reviews in medicinal chemistry

|September 5, 2025

まとめ

ブルトン

科学分野:

免疫学と薬理学
分子生物学と薬剤の発見

背景:

B細胞受容体 (BCR) のシグナル伝達経路は免疫において極めて重要であり,新しい治療法によって標的とされています.
ブルートンのチロシンキナーゼ (BTK) はBCRシグナル伝達における重要なキナーゼであり,重要な薬物標的である.

研究の目的:

最近のBTK阻害剤の進歩とその治療的応用について見直す.
治療戦略を最適化するためにBTK抑制の薬理学的メカニズムを探求する.
精密医療と薬物再利用における BTK 阻害剤の役割を強調する.

主な方法:

2025年6月までのBTK阻害剤に関する研究に関する包括的な文献レビュー.
薬理学的メカニズムとBTK経路を標的とする臨床的関連性の分析

主要な成果:

BTK阻害剤は,BCRシグナル伝達と炎症経路を調節することによって,高度な治療選択肢を提供します.
BTK抑制メカニズムの理解は,患者の反応を予測し,組み合わせ治療を導くのに役立ちます.
トランスレーション研究とBTKを標的とする治療の薬物の再利用において顕著な進展.

結論:

BTK抑制は,様々な免疫関連疾患の治療に有望な戦略です.
薬理学的メカニズムに関するさらなる研究は,精密医療のアプローチの開発を促進します.
BTK阻害剤は患者の治療結果を改善する価値のある付加物です

キーワード:

ベータ細胞受容体ブルートンチロシンキナーゼコロナウイルス自己免疫疾患移植対宿主病です血液学的悪性腫瘍

さらに関連する動画

10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

790

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:27

Tumor Immunotherapy

658

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

658

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.8K

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

2.8K

01:26

Receptor Tyrosine Kinases

13.9K

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

13.9K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...